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World antibiotic awareness week, is a campaign led by the World Health Organisation and 
was run on November 13-19th this year. The aim of the campaign is to raise awareness of 
the threat of antibiotic resistance to clinical care. Within the UK the Association of Clinical 
Oral Microbiologists (ACOM) working in partnership with a number of organisations 
including the Faculty of General Dental Practitioners utilises an annual Thunderclap 
campaign to raise the awareness of appropriate antimicrobial use in dentistry. During the 
last 18 months I have been made increasingly aware of the emergence of bacterial 
resistance to metronidazole, a barrier I thought was too costly (in terms of bacterial 
metabolism) for anaerobes to cross and result in clinically relevant infections. I should have 
known better.  
Metronidazole is a member of the nitroimidazole group of compounds with anti-microbial 
and anti-protozoan activity (such as Trichomonas vaginalis) developed in the late 1950’s. Its 
link to the management of dental infections was first reported in 1962 as a co-incidental 
finding of the “double” resolution of trichomonal vaginitis and “acute marginal gingivitis” 
and the rest as they say is history1. In common with other anti-microbial agents resistance 
to metronidazole can take many forms especially under selection pressure according to 
basic Darwinian principles when levels of the antimicrobial in the environment rise. The 
main driver for the development of antimicrobial resistance is exposure to antibiotics, high 
levels of antibiotic use are correlated with high levels of resistance2. But first let’s look at 
some clinical evidence. I first became alerted to the clinical implications of metronidazole 
resistance when in a relatively short time, we became aware in Glasgow of at least two 
clinically significant infections caused by metronidazole resistant bacteria. One of these was 
a knee joint infection with an anaerobic streptococci (also found in periodontal disease and 
dental abscesses) and the other was a Bacteroides  thetaiotaomicron blood stream 
infection. These isolates are reported in last years report of antimicrobial resistance in 
Scotland3 where metronidazole resistance was included in annual surveillance data for the 
first time. Looking more widely other workers have noted the appearance of metronidazole 
resistance in microbial species that can also be recovered from dental infections 4,5. The 
logical extension of this data is that it will only be a matter of time before metronidazole 
resistance in oral infections is reported. Metronidazole resistance can occur by a number of 
different mechanisms that involve reduced uptake of the drug, increased removal from the 
bacterial cell or by reducing the rate of metronidazole activation inside anaerobes. Of 
immediate concern is the occurrence of specific resistance genes (nim) which code for an 
alternative set of enzymes that can convert activated forms of metronidazole into non-toxic 
derivatives6. A family of nim genes is known to exist and can spread between different 
classes of bacteria. 
It is difficult to define the extent of the problem of metronidazole resistance, firstly there is 
the paradox of detecting metronidazole resistance in the laboratory. Screening of primary 
agar plates from infection specimens for the presence of anaerobes is usually performed by 
assessing zones of inhibition caused by a metronidazole disc. Following anaerobic growth, 
any microbe that is not inhibited by metronidazole is discarded since a commonly used  
definition of an anaerobe is an isolate that is inhibited by metronidazole ! In clinical dental 
practice a further challenge to understanding the extent of the problem is the collection, 
submission, reporting and surveillance of dento-alveolar infections. There is no quick and 
easy fix for this, there are multiple challenges and we have tried (and failed) in Glasgow to 
facilitate this7. However, this does not mean the issue should not be re-examined and utilise 
new technologies. We do know that increased levels of prescribing lead to increased 
patterns of resistance and perhaps an easier fix than obtaining surveillance data is to review 
dental prescribing of metronidazole. 
Current prescribing data by GDP’s in England and Scotland demonstrates that approximately 
60% and 52% respectively of the total metronidazole prescribed in Primary Care is for dental 
infections8,9. It is difficult to understand why metronidazole is so widely prescribed in dental 
practice as the first line of treatment for acute dental infections should be infection source 
control i.e., surgical treatment (extraction, endodontics, incision and drainage, debridement 
etc). If required then the first line antimicrobial agent is a beta-lactam (Penicillin, 
Amoxicillin)10. The dental team should become more aware of the importance of 
antimicrobial stewardship to conserve metronidazole.  
There is also an important role here for the current senior leaders in Dentistry, antimicrobial 
stewardship is a team process with Clinical Oral Microbiologists playing a vital role within 
the team. Clinical Oral Microbiologists have the training, dental background, expertise and   
competencies to facilitate antimicrobial stewardship, yet there are only 8 on the GDC 
Specialist Register (and not all of these are in clinical practice). ACOM believes there is 
overwhelming evidence now that all dental hospitals and schools should have access to a 
Consultant Clinical Oral Microbiologist not just for stewardship expertise but also their 
expertise in infection prevention and control. These two subjects are not mutually exclusive. 
I just hope that enough Clinical Oral Microbiologists can be trained in time for the next 
generation of the dental team before we completely lose metronidazole from the drug 
cabinet. 
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